How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.
Community PollStarted
Which of the following barriers have you encountered when prescribing blinatumomab?
7 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Washington
Answered on
This is a very challenging issue that speaks to an incredibly important aspect of delivering not only this drug but others like it. Despite the strong evidence that supports the use of blinatumomab in a variety of clinical scenarios for patients with B-cell ALL [e.g., Gökbuget et al., PMID 29358182;...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Emory University
Answered on
I agree with all of Dr. @Dr. First Last's answers. We have found it easier than expected to provide blinatumomab for all of the children we feel could benefit from it. Some issues that came up and were dealt with:
- Preauthorization: for patients who meet the approved indication, MRD positivity after...
Join for free or sign in to see the full answer